Drug class profile · refreshed daily from federal data

Monoamine Oxidase Inhibitor

2 molecules in this class, $69.9M combined CY2024 Part D spend across 309K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Monoamine Oxidase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $69.9Mcombined across class
Total Rx claims: 309K80K unique beneficiaries
Generic mfrs (active): 14across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Rasagiline

Brand: Azilect · 226K Part D claims (CY24) · 59K beneficiaries · First FDA approval: 2006-07-10

10 generic mfrs 0 plans require PA

Low NADAC$0.667

→

Avg plan cost$3.22

Part D spend $42.1M 5× spread, current vs floor

Class share

60%

of class CY24 spend

View profile →

Selegiline

Brand: EMSAM · 82K Part D claims (CY24) · 22K beneficiaries · First FDA approval: 1996-08-02

4 generic mfrs 543 plans require PA

Low NADAC$0.652

→

Avg plan cost$23.03

Part D spend $27.9M 35× spread, current vs floor

Class share

40%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.